Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin microbiological study in non-constipation irritable bowel syndrome
2010-024177-39Phase 2Terminated
- Sponsor
- Alfa Wassermann
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rifaximin in irritable bowel syndrome (IBS) (2 arms), sponsored by Alfa Wassermann. Primary endpoints: Difference in fecal microbiota between healthy volunteers and non-constipation IBS patients, Effect of rifaximin on fecal microbiota composition and 1 more. Started Feb 2011; status: terminated.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2010-024177-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024177-39.